GRAL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Grail Inc (GRAL) is not a good buy at the moment for a beginner investor with a long-term strategy. The stock has experienced a significant post-market drop of 48.55% due to missing the primary endpoint in its NHS-Galleri trial, which has raised concerns about its growth prospects. Additionally, financial performance has deteriorated, with net income and EPS dropping to zero. While analysts see potential in the long term, they highlight risks and suggest waiting for a better entry point. The lack of positive trading signals and the current technical indicators do not support an immediate buy.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 54.286, showing no clear signal. Moving averages are converging, suggesting indecision in the market. Key support and resistance levels are at S1: 94.023 and R1: 106.663, with the stock currently below the pivot point of 100.343.
The Galleri test has shown improvement in Stage IV cancer detection rates.
and an IV rank of 308.62 indicate extreme uncertainty.
In Q4 2025, revenue increased by 13.97% YoY to $43.6 million. However, net income and EPS dropped to zero, and gross margin declined by 38.81% YoY to -25.54%. These figures indicate financial instability and poor profitability.
Analysts are mixed but cautious. TD Cowen initiated a Hold rating with a $114 price target, citing risks despite long-term potential. Baird initiated an Outperform rating with a $113 price target, highlighting upcoming milestones as potential catalysts. Guggenheim raised its price target to $130, maintaining a Buy rating, but the stock's recent performance raises concerns.
